Advertisement

Contraception for Breast Feeding Mothers with the 75 Microgram Desogestrel-Only Pill: An Indian Perspective

  • Sheela Mane
  • Saravanan VeeramalaiEmail author
  • Meera V. V. Ragavan
Invited Review Article
  • 90 Downloads

Abstract

Contraception for nursing mothers is an important aspect from the point of view of birth spacing as well as maternal and infant well-being. An ideal contraceptive for this period would be one that is highly efficacious, fairly safe and reversible, with no negative impact on breast milk and infant growth. The 75 microgram (mcg) desogestrel-only pill is the only Progestogen only pill (POP) available in India. The objective of this article is to evaluate if Desogestrel 75 mcg POP stands out as a near ideal method for contraception in the post-partum women by reviewing data available from Indian clinical studies primarily and also some evidences from international studies.

Keywords

Progestogen only pill Desogestrel only pill Cerazette 

Notes

Compliance with Ethical Requirements and Conflict of Interest

This manuscript is a review article, does not include any patient data and hence did not require an approval by an ethics committee. Dr. Sheela Mane and Dr. Meera Ragavan declare no conflict of interest or funding relevant to this manuscript that may bias their opinion. Dr. Saravanan Veeramalai is an employee of MSD Pharmaceuticals Private Limited.

References

  1. 1.
    International Institute for Population Sciences (IIPS) and Macro International. National Family Health Survey (NFHS-3), 2005–06: India: Volume I. Mumbai: IIPS;2007. http://www.measuredhs.com/pubs/pdf/FRIND3/00FrontMatter00.pdf. Accessed 3 June 2014.
  2. 2.
    Marston Cicely. Report of a WHO Technical Consultation on Birth Spacing Geneva Switzerland 13–15 June 2005. Geneva, Switzerland, World Health Organization [WHO], 2006. 37 p http://www.who.int/maternal_child_adolescent/documents/birth_spacing.pdf. Accessed 18 June 2014.
  3. 3.
    García PV, Mella C. Analysis of factors involved in lactational amenorrhea. J Biosaf Health Educ. 2013;1(109):2332-–0893.Google Scholar
  4. 4.
    National guidelines on infant and young child feeding. Ministry of Human Resource Development. Department of Women and Child development (Food and Nutrition Board). Government of India.; 2004. p 2–3. http://wcd.nic.in/nationalguidelines.pdf.Accessed 3 June 2014.
  5. 5.
    WBTi: India Report 2012 (World Breast feeding Trends Initiative) http://www.worldbreastfeedingtrends.org/report/WBTi-India-2012.pdf. Accessed 3 June 2014.
  6. 6.
    Flynn AM, Docker M, Brown JB, et al. Ultrasonographic patterns of ovarian activity during breastfeeding. Am j obst Gynecol. 1991;165(6 Pt 2):2027–31.CrossRefGoogle Scholar
  7. 7.
    World Health Organization. Medical eligibility criteria for contraceptive use; 2004. Reproductive Health and Research, World Health Organization WHO/RHR/00.02, Geneva (2008).Google Scholar
  8. 8.
    Vessey M, Lawless M, Yeates D. Efficacy of different contraceptive methods. Lancet. 1982;319(8276):841–2.CrossRefGoogle Scholar
  9. 9.
    Cerazette® Patient Information booklet 2014.Google Scholar
  10. 10.
    Kloosterboer HJ, Vonk-Noordegraaf CA, Turpijn EW. Selectivity in progesterone and androgen receptor binding of progestagens used in oral contraceptives. Contraception. 1988;38(3):325–32.CrossRefGoogle Scholar
  11. 11.
    The Medical Eligibility Criteria Wheel for Contraceptive use––India (2010) (India MEC Wheel)––Govt of India (Adopted from WHO Medical Eligibility Criteria for Contraceptive Use, 3rd Edition 2004 and 2008 Update).Google Scholar
  12. 12.
    Kennedy KI, Short RV, Tully MR. Premature introduction of progestin-only contraceptive methods during lactation. Contraception. 1997;55(6):347–50.CrossRefGoogle Scholar
  13. 13.
    Rice CF, Killick SR, Dieben T, et al. A comparison of the inhibition of ovulation achieved by desogestrel 75 μg and Levonorgestrel 30 μg daily. Hum Reprod. 1999;14(4):982–5.CrossRefGoogle Scholar
  14. 14.
    Ray Subrat, Sovani VB. A postmarketing observational study assessing acceptability and reliability of desogestrel only contraceptive pill (Cerazette) in Indian women. J Indian Med Assoc. 2006;104(11):653–6.Google Scholar
  15. 15.
    Dutta DK, Dutta I. Desogestrel mini pill: is this safe in lactating mother? J Indian Med Assoc. 2013;111(8):553–5.Google Scholar
  16. 16.
    Korver T. A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 μg/day or levonorgestrel 30 μg/day: collaborative study group on the desogestrel-containing progestogen-only pill. Eur J Contracept Reprod Health Care. 1998;3(4):169–78.CrossRefGoogle Scholar
  17. 17.
    Korver T, Klipping C, Heger-Mahn D, et al. Maintenance of ovulation inhibition with the 75 μg desogestrel-only contraceptive pill (Cerazette®) after scheduled 12-h delays in tablet intake. Contraception. 2005;71(1):8–13.CrossRefGoogle Scholar
  18. 18.
    Bjarnadóttir RI, Gottfredsdóttir H, Sigurdardóttir K, et al. Comparative study of the effects of a progestogen‐only pill containing desogestrel and an intrauterine contraceptive device in lactating women. BJOG: Int J Obst Gynaecol. 2001;108(11):1174–80.Google Scholar
  19. 19.
    Kovacs Gab. Progestogen-only pills and bleeding disturbances. Hum Reprod. 1996;11(suppl 2):20–3.CrossRefGoogle Scholar
  20. 20.
    Belsey EM, d’Arcangues Catherine. The analysis of vaginal bleeding patterns induced by fertility regulating methods. Contraception. 1986;34(3):253–60.CrossRefGoogle Scholar
  21. 21.
    Bitzer J, Gemzell-Danielsson K, Roumen F, et al. “The CHOICE study: effect of counselling on the selection of combined hormonal contraceptive methods in 11 countries. Eur J Contracept Reprod Health Care. 2012;17(1):65–78.CrossRefGoogle Scholar
  22. 22.
    Sheriar N, Joshi R, Mukherjee B, et al. Impact of structured counseling on the selection of hormonal contraceptive methods: results of a multi-centric, observational study in India. J Obst Gynaecol India. 2014;64(4):1–10.Google Scholar
  23. 23.
    Merki-Feld GS, Imthurn B, Seifert B, et al. Desogestrel-only contraception may reduce headache frequency and improve quality of life in women suffering from migraine. Eur J Contracept Reprod Health Care. 2013;18(5):394–400.CrossRefGoogle Scholar
  24. 24.
    Ahrendt HJ, Karckt U, Pichl T, et al. The effects of an oestrogen-free, desogestrel-containing oral contraceptive in women with cyclical symptoms: results from two studies on oestrogen-related symptoms and dysmenorrhoea. Eur J Contracept Reprod Health Care. 2007;12(4):354–61.CrossRefGoogle Scholar
  25. 25.
    Morotti M, Buccelli E, Valentino R, et al. M054 Progestogen-only contraceptive pill compared with combined oral contraceptive in the treatment of pain symptoms caused by endometriosis in patients with migraine without aura. Int J of Gyn Obs. 2012 Oct; 119:S548. Available from: http://dx.doi.org/10.1016/s0020-7292(12)61248-x.

Copyright information

© Federation of Obstetric & Gynecological Societies of India 2014

Authors and Affiliations

  • Sheela Mane
    • 1
  • Saravanan Veeramalai
    • 2
    • 4
    • 5
    Email author
  • Meera V. V. Ragavan
    • 3
  1. 1.Fortis Hospitals and Anugraha Nursing HomeBangaloreIndia
  2. 2.MSD Pharmaceuticals PVT LTDChennaiIndia
  3. 3.Apollo Hospitals PVT LTDChennaiIndia
  4. 4.MSD Pharmaceuticals Private Limited (A Subsidiary of Merck & Co. Inc.)Whitehouse StationUSA
  5. 5.MumbaiIndia

Personalised recommendations